Literature DB >> 18556193

Significance of micrometastases in prostate cancer.

Masato Fujisawa1, Hideaki Miyake.   

Abstract

Pelvic lymph node metastases have been considered the most potent factor associated with disease recurrence in patients undergoing radical prostatectomy for localized prostate cancer. Routine pathological examination, however, can miss micrometastatic tumor foci in the lymph nodes of patients with prostate cancer, resulting in confused tumor staging and clinical decision-making. Accordingly, intensive efforts have been made to develop a procedure for efficaciously detecting micrometastases in pelvic lymph nodes using several kinds of molecular and histopathological techniques targeting genes specifically expressed in the prostate, such as prostate-specific antigen and prostate-specific membrane antigen. Although some of these techniques have been shown to achieve significantly higher sensitivity for detecting micrometastatic prostate cancer cells in surgically removed pelvic nodes during radical prostatectomy than conventional pathological examination, there have not been any methods introduced into clinical practice. In this review, we attempted to summarize recent advances in the field of "micrometastases" in prostate cancer in order to clarify the clinical significance of micrometastases in patients undergoing radical prostatectomy and to suggest limitations to be overcome before developing a reliable model for clinical application.

Entities:  

Mesh:

Year:  2008        PMID: 18556193     DOI: 10.1016/j.suronc.2008.05.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  6 in total

Review 1.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

2.  Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data.

Authors:  Caroline Rousseau; Thierry Rousseau; Cédric Mathieu; Jacques Lacoste; Eric Potiron; Geneviève Aillet; Pierre Nevoux; Georges Le Coguic; Loïc Campion; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-11       Impact factor: 9.236

Review 3.  Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

Authors:  T Pencavel; R Seth; A Hayes; A Melcher; H Pandha; R Vile; K J Harrington
Journal:  Gene Ther       Date:  2010-05-06       Impact factor: 5.250

4.  Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma.

Authors:  Caroline Rousseau; Thierry Rousseau; Boumédiène Bridji; Amandine Pallardy; Jacques Lacoste; Loïc Campion; Aude Testard; Geneviève Aillet; Ayat Mouaden; Chantal Curtet; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-16       Impact factor: 9.236

5.  Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy.

Authors:  Trinity J Bivalacqua; Phillip M Pierorazio; Michael A Gorin; Mohamad E Allaf; H Ballentine Carter; Patrick C Walsh
Journal:  Urology       Date:  2013-09       Impact factor: 2.649

6.  In vitro cytotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab.

Authors:  Muhamad Faiz Bin Othman; Elise Verger; Ines Costa; Meena Tanapirakgul; Margaret S Cooper; Cinzia Imberti; Valerie J Lewington; Philip J Blower; Samantha Y A Terry
Journal:  Nucl Med Biol       Date:  2019-12-13       Impact factor: 2.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.